Japanese Encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental “dead end” hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE.

Vaccines for JE have been available for decades and used in large scale routine immunization programs in South Korea, China and Japan. Older mouse brain derived vaccines are gradually being replaced by live-attenuated (SA 14-14-2, CIBP) and new vero cell derived inactivated vaccines from both local and Western manufacturers. Countries currently not operating JE vaccination programs are predicted to do so in the next 5 years so increasing demand.

This **MarketVIEW** product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. **LO, BASE & HI** forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Japanese Encephalitis epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by VacZine Analytics in field of travel and endemic vaccines has also been utilised. ***See Bibliography for exact sources.

PRODUCT CONTENTS:
Updated Jan 2012 (CAT No: VAMV011)

****This product is composed of two models and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Contents
Authors note
Executive summary
Commercial model: key outputs
JE vaccine: available market (endemic/public) ($ 000s) – all children to 2030
JE vaccine: available market (endemic/public) ($ 000s) – infants to 2030
JE vaccine: available market (endemic/public) ($ 000s) – 1 to 15 yrs to 2030
JE vaccine: endemic segment volume analysis (mio doses/yr)
JE vaccine: available market (endemic/private) ($ 000s) – 1 to 15 yrs to 2030
JE vaccine: market by vaccine type 2015
JE vaccines: all market segments, revenues/yr (2015)
JE: disease background
JE: transmission cycle
JE: geographic distribution
JE: epidemiology
JE: genotype distribution
JE: country reporting/surveillance
JE: WHO reported cases 2006 - 2010
JE: disease profile of main endemic countries
Risk of JE by country, region and season
DALYs per 100,000 persons in JE endemic countries
JE: disease trends and dynamics
JE: factors contributing to increasing transmission
JE and travelers
JE: control and prevention
JE control: aligned with major stakeholder objectives
PATH JE project: strategic goals
JE vaccines: policy evolution
JE vaccines: immunological aspects
Impact of JE vaccination
JE vaccination and cost effectiveness
Currently licensed JE vaccines (endemic)
Country status of JE control through immunization
Country use of JE vaccine types: SEA region
Country use of JE vaccine types: WPR region
CONTINUED.....

JE focus on India
India: cases and deaths 1993 – 2009
India – JE priority districts
India – mass vaccination campaigns
India – mass vaccination campaigns: progress to date
Transition to new JE vaccines
Availability of new JE vaccines
JE vaccination: country future planning – SEA region
JE vaccination: country future planning – WPR region
Commercial model: detailed assumptions per WHO region/country
JE vaccine demand forecast: countries modelled
JE vaccines: modelling strategy
Commercial model assumptions – SEA region
Commercial model assumptions – WPR region
Pricing case studies for endemic vaccines
JE vaccine prices used in model
Source material
JE vaccines (PATH): estimated implementation 2006 – 2015
Japan: immunization schedule 2011 (< 20 yrs)
Japan: JEV vaccinations given 1995 – 2009 (000s)
Ensebakku subcutaneous JE vaccine: History of development
Ixiaro/JESPECT – distribution structure
Bibliography
About VacZine Analytics
Disclaimer
Back page

PAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based) – endemic markets (public/private)

Title sheet
CHARTS – VAL (private)
CHARTS – VAL (pub)
CHARTS – VOL (pub)
GRAND VALUE SUMMARY
Value by vaccine type
Value Summary (pub <1 yrs)
Value Summary (pub 1-15 yrs)
Value Summary (priv 0 - 15 yrs)
Global price summary
Volume Summary (pub <1 yrs)
Volume Summary (pub 1-15 yrs)
Volume Summary (priv 0 - 15 yrs)
Volume Summaries
SEA region
Bangladesh (pub)
Bangladesh (priv)
Bhutan (pub)
Bhutan (priv)
India (pub)
India (priv)
Indonesia (pub)
CONTINUED.....

Indonesia (priv)
Korean DPR (pub)
Timor Leste (pub)
Timor Leste (priv)
Myanmar (pub)
Myanmar (priv)
Nepal (pub)
Nepal (priv)
Pakistan (pub)
Pakistan (priv)
Sri Lanka (pub)
Sri Lanka (priv)
Thailand (pub)
Thailand (priv)
WPR region =>
Australia (pub)
Brunei (pub)
Brunei (priv)
Cambodia (pub)
Cambodia (priv)
China (pub)
Taiwan (pub)
Japan (pub)
Korea – republic (pub)
LAO PDR (pub)
LAO PDR (priv)
Malaysia (pub)
Malaysia (priv)
Papua New Guinea (pub)
Papua New Guinea (priv)
Philippines (pub)
Philippines (priv)
Russia FE (pub)
Russia FE (priv)
Vietnam (pub)
Epidemiology =>>
Endemic countries
JEV number of cases
Population databases
Birth cohorts – SEA
2 – 49 yrs SEA
Birth cohorts – WPR
2 – 49 yrs WPR
JEV – Japan data
Urban/rural split
Measles vaccine prices
Back page

WORKSHEETS: ~65
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00/ GBP £5695.00# (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
#Indicative – exchange made on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY:

16. WHO SEA/WPRO and PATH’s JE Project. Report of the Bi-Regional meeting on JE, Bangkok, Thailand, 30 Mar - 1 Apr 05.
20. PATH’s Japanese encephalitis project. Collaboration and commitment to protect Asia’s children. Published by PATH. December 2009


42. How might dengue vaccine be used in Thailand. Presentation by Charung Muangchan. National Vaccine Committee Office. Department of Disease Control.


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009